ERBB2 and gastric cancer: In the first phase 1 dose-escalation study, 22 patients with HER-2 positive advanced or metastatic breast cancer, gastric cancer, or other HER-2 expressing solid tumors were treated with 0.8 mg/kg to 8.0 mg/kg of trastuzumab deruxtecan once every three weeks [136].